HIV-1-RNA and total HIV-1-DNA loads in the genital compartment in men receiving dolutegravir- versus darunavir-based combined ART (cART) regimens during primary HIV infection.
Alice-Andrée MariaggiRebecca BauerCaroline CharreElise GardiennetVincent MeiffredyFaiza AjanaKarine LacombeGilles PialouxEric CuaChristine RouziouxLaurence MeyerAntoine CheretVéronique Avettand-FenoelPublished in: The Journal of antimicrobial chemotherapy (2022)
For the first time, to the best of our knowledge, we showed that a dolutegravir-based regimen initiated as soon as PHI reduces HIV-RNA and HIV-DNA with no difference compared with a control group receiving a darunavir-based regimen. Although the viral purge in semen seems longer after treatment in PHI than CHI, due to high viral loads, early dolutegravir-based treatment initiation permits a major decay of both viral particles and infected cells in semen, efficiently reducing the high risk of transmission during PHI.
Keyphrases
- antiretroviral therapy
- hiv infected patients
- hiv infected
- hiv positive
- human immunodeficiency virus
- hiv aids
- hiv testing
- sars cov
- hepatitis c virus
- men who have sex with men
- circulating tumor
- nucleic acid
- cell free
- healthcare
- single molecule
- induced apoptosis
- cell proliferation
- cell cycle arrest
- endoplasmic reticulum stress
- circulating tumor cells